IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
Kadmon preps filing for GVHD drug belumosudil after phase 3 winNew York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus Share XKadmon preps filing for GVHD drug belumosudil after phase 3 winhttps://pharmaphorum.com/news/kadmon-preps-filing-for-gvhd-drug-belumosudil-after-phase-3-win/
Innovating in inflammation and immunologyFor World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for Share XInnovating in inflammation and immunologyhttps://pharmaphorum.com/r-d/views-analysis-r-d/innovating-in-inflammation-and-immunology/
Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
Ligelizumab could top Xolair in chronic hives, says NovartisNovartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XLigelizumab could top Xolair in chronic hives, says Novartishttps://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
J&J filing aims Tremfya at crowded psoriatic arthritis marketJohnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, Share XJ&J filing aims Tremfya at crowded psoriatic arthritis markethttps://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/
FDA agrees to downsized trial for Calliditas’ rare disease drugThe FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, Share XFDA agrees to downsized trial for Calliditas’ rare disease drughttps://pharmaphorum.com/news/fda-agrees-to-downsized-trial-for-calliditas-rare-disease-drug/
